The U.S. Food and Drug Administration said on Wednesday it has withdrawn its approval for TG Therapeutics Inc.’s lymphatic cancer treatment Ukoniq over concerns of higher risk of death in patients receiving the drug.
Ukoniq received accelerated approval in the United States in February last year to treat adult patients with marginal zone lymphoma who have received prior therapy and for the treatment of adult patients with follicular lymphoma.
